CTRI/2021/03/032140已完成未知
An open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, truncated (only for chlorthalidone) crossover oral bioequivalence study of test product, fixed dose combination of Efonidipine HCl ethanolate 40 mg and Chlorthalidone 12.5 mg tablets of Zuventus Healthcare Limited, India with reference products, Efnocar 40 (Efonidipine HCl ethanolate 40 mg) tablets, manufactured by Zuventus Healthcare Limited, India and CTD�®-12.5 (Chlorthalidone 12.5 mg) tablets, manufactured by Ipca Laboratories Limited, India in normal, healthy, adult, human subjects under fasting conditions.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy human subjects between 18-45 years of age (including both) and weight ââ?°Â¥ 50 Kg (BMI 18.5 to 24.9 kg/mÃ?² (including both)).
- •2. Acceptable findings during registration and screening including, medical history, physical examination, laboratory evaluations, 12- lead ECG and Chest X-Ray (postero-anterior view).
- •3. Values within normal ranges for laboratory parameters upon evaluation by the Investigator or Physician for any of the following tests.
- •4. Subjects able to communicate effectively.
- •5. Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
- •6. Subject willing to abstain from all kinds of alcoholic beverages, grapefruit/caffeine/xanthine containing foods or juices from at least 72.00 hours prior to admission until the last blood sample collection in each study period.
- •7. Must be non-smokers or ex-smokers: An ex-smoker is defined as someone who completely stopped smoking for at least 6 months before Day 1 (first dosing) of Period-I of this study.
- •8. Female subjects:
- •Ã¯â??· Postmenopausal for at least 1 year or
- •Ã¯â??· Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject) or
- •Ã¯â??· Female of childbearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, and intrauterine device (IUD) or abstinence.
排除标准
- •1. Subjects having contraindication or hypersensitivity (e.g., anaphylaxis) to Efonidipine and Chlorthalidone or related group of drugs or any of its excipients.
- •2. A history or presence of significant asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs, seizures, diabetes, migraine, hypertension, cardiovascular, pulmonary, neurological or psychiatric disease/disorder, dermatological, endocrine, immunological, hepatic, renal, hematopoietic, gastrointestinal, ongoing infectious diseases, or any other significant abnormality as evidenced by medical history and physical examination or according to the opinion of the physician.
- •3. History or presence of gastrointestinal (GI) inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine.
- •4. History or evidence of exfoliative dermatitis, Stevens - Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).
- •5. Any known enzyme inducing or inhibiting drug taken within 30 days before the study.
- •6. Participation in a drug research study within 90 days prior to dosing of this study.
- •7. Blood loss or whole blood donation within 90 days prior to drug administration.
- •8. Consumption of high caffeine (more than 5 cups of coffee or tea/day).
- •9. History of addiction to any recreational drug or drug dependence.
- •10. An unusual or abnormal diet, for whatever reason within 48.00 hours prior to admission of each period, e.g. fasting due to religious reasons.
- •11. History of dehydration from diarrhea, vomiting or any other reason within a period of 72.00 hours prior to study admission of each period.
- •12. Positive results for drugs of abuse (benzodiazepines, cocaine, opioids, amphetamines, cannabinoids and barbiturates) in urine during the study admission of each period.
- •13. Positive results for alcohol breathe analysis during the study admission of each period.
- •14. History of pre-existing bleeding disorder.
- •15. Difficulty in swallowing solids like tablets.
- •16. Difficulty with donating blood.
- •17. Systolic blood pressure less than 120 mm Hg or more than 140 mm Hg.
- •18. Diastolic blood pressure less than 70 mm Hg or more than 90 mm Hg.
- •19. Pulse rate less than 60 beats/minute or more than 100 beats/minute.
- •20. Use of any prescribed medication or OTC medicinal products during last two weeks preceding the first dosing.
- •21. Female subjects demonstrating a positive pregnancy screen.
- •22. Female volunteer who is pregnant, currently breast-feeding.
- •23. Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
研究者
相似试验
尚未招募
不适用
Comparative bioavailability study of Test product Alogliptin and Pioglitazone tablets 12.5 mg/45 mg compared with the reference product of Oseni (alogliptin and pioglitazone) tablets 12.5 mg/ 45 mg, in healthy, adult, human subjects, under fed conditions.CTRI/2019/04/018646Indoco Remedies Limited
招募中
不适用
To compare Bioequivalence study of Sitagliptin 100 mg Metformin Hydrochloride 1000 mg extended release Tablets in healthy adult human subjects under fasting conditionsCTRI/2023/02/049858SunGlow Lifescience Private Ltd
尚未招募
不适用
Comparative bioavailability study of Test product Fesoterodine Fumarate ER Tablets 8 mg compared with the reference product of Toviaz® (fesoterodine fumarate) Extended-Release Tablets 8 mg, in healthy, adult, human subjects, under fasting conditions.CTRI/2019/04/018645MSN Laboratories Private Limited
进行中（未招募）
Unknown
Bioequivalence study of Esomeprazole 20 mg Naproxen 500 mg Delayed Release Tablets in healthy adult human subjects under fasting conditioCTRI/2023/04/051767Faromed Lifesciences LLP (Subsidiary of Omnicals Pharma Private Limited)
尚未招募
不适用
Comparative bioavailability study of Test product Fesoterodine Fumarate ER Tablets 8 mg compared with the reference product of Toviaz® (fesoterodine fumarate) Extended-Release Tablets 8 mg, in healthy, adult, human subjects, under fed conditions.CTRI/2019/04/018644MSN Laboratories Private Limited